09:44 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the three-month period ended June 30, 2022. Unless otherwise noted, all amounts are in U.S. dollars Total revenue for the quarter was $0.75 million compared to $0.56 million in the prior-year period. EBITDA was a loss of $6.7 million in the second quarter of 2022 compared to a loss of $6.5 million in the prior-year period. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $3.00.
